Mar 5, 2025, 10:04
Myeloma Paper of the Day, March 5th, suggested by Robert Orlowski
Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Management of CRS related to teclistamab in patients with relapsed/refractory myeloma can be successful with as little as one dexamethasone dose of 10 mg and without compromising the response rate.”
Authors: James Davis, Jordan Snyder, Mikhaila Rice, Zahra Mahmoudjafari, Victoria Nachar et al.
More posts featuring Robert Orlowski.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 6, 2025, 01:10
Jun 5, 2025, 15:47
Jun 5, 2025, 15:44
Jun 5, 2025, 15:07